Eosinophilic esophagitis incidence in New Zealand: high but not increasing.
eosinophilic esophagitis
epidemiology
incidence
Journal
Clinical and experimental gastroenterology
ISSN: 1178-7023
Titre abrégé: Clin Exp Gastroenterol
Pays: New Zealand
ID NLM: 101532800
Informations de publication
Date de publication:
2019
2019
Historique:
received:
21
05
2019
accepted:
16
07
2019
entrez:
20
9
2019
pubmed:
20
9
2019
medline:
20
9
2019
Statut:
epublish
Résumé
Eosinophilic esophagitis (EoE) is an immune-mediated inflammatory condition of the esophagus. Recent literature has shown an increasing incidence of the disease. However, no epidemiological data exist regarding New Zealand rates of EoE. The disease is associated with atopy, and New Zealand's high rate of atopic disease means the disease may be important in our population. We carried out a retrospective study to describe the incidence of EoE in the Wellington region of New Zealand, as well as key histological and clinical factors associated with the disease. A search was made of laboratory and endoscopic databases in the Wellington region to identify all diagnosed cases in the five years between January 1, 2011, and December 31, 2015. Case notes were examined to determine the key demographic and clinical parameters in the cases. Incidence rates were calculated for each year, and the effects of age group and sex on the incidence rates were analyzed. We found 152 cases of EoE in the Wellington region with an annual incidence of 6.95 per 100,000 person/years. We found no evidence of a significant difference in incidence rates by year in our study population. There was a significantly lower incidence rate in those aged <16 compared to those aged ≥16 (RR=0.26). Males had a higher incidence rate than females with an estimated rate ratio of 2.45 ( Our results are in contrast to previous reports of increasing incidence rates and may reflect a leveling off of incidence. Further research is needed to determine whether the low incidence in our pediatric age group is due to ascertainment bias or due to a real difference in the epidemiology of EoE in NZ compared to other countries.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Eosinophilic esophagitis (EoE) is an immune-mediated inflammatory condition of the esophagus. Recent literature has shown an increasing incidence of the disease. However, no epidemiological data exist regarding New Zealand rates of EoE. The disease is associated with atopy, and New Zealand's high rate of atopic disease means the disease may be important in our population. We carried out a retrospective study to describe the incidence of EoE in the Wellington region of New Zealand, as well as key histological and clinical factors associated with the disease.
METHOD
METHODS
A search was made of laboratory and endoscopic databases in the Wellington region to identify all diagnosed cases in the five years between January 1, 2011, and December 31, 2015. Case notes were examined to determine the key demographic and clinical parameters in the cases. Incidence rates were calculated for each year, and the effects of age group and sex on the incidence rates were analyzed.
RESULT
RESULTS
We found 152 cases of EoE in the Wellington region with an annual incidence of 6.95 per 100,000 person/years. We found no evidence of a significant difference in incidence rates by year in our study population. There was a significantly lower incidence rate in those aged <16 compared to those aged ≥16 (RR=0.26). Males had a higher incidence rate than females with an estimated rate ratio of 2.45 (
CONCLUSION
CONCLUSIONS
Our results are in contrast to previous reports of increasing incidence rates and may reflect a leveling off of incidence. Further research is needed to determine whether the low incidence in our pediatric age group is due to ascertainment bias or due to a real difference in the epidemiology of EoE in NZ compared to other countries.
Identifiants
pubmed: 31534357
doi: 10.2147/CEG.S216126
pii: 216126
pmc: PMC6681430
doi:
Types de publication
Journal Article
Langues
eng
Pagination
367-374Déclaration de conflit d'intérêts
The authors have no competing interests to declare in this work.
Références
Clin Gastroenterol Hepatol. 2005 Dec;3(12):1198-206
pubmed: 16361045
N Z Med J. 2006 Mar 10;119(1230):U1889
pubmed: 16532053
Lancet. 2006 Aug 26;368(9537):733-43
pubmed: 16935684
Thorax. 2007 Sep;62(9):758-66
pubmed: 17504817
Gastroenterology. 2007 Oct;133(4):1342-63
pubmed: 17919504
Clin Gastroenterol Hepatol. 2009 Oct;7(10):1055-61
pubmed: 19577011
Am J Gastroenterol. 2010 May;105(5):1015-23
pubmed: 19904246
J Allergy Clin Immunol. 2011 Jul;128(1):3-20.e6; quiz 21-2
pubmed: 21477849
Gut. 2013 Apr;62(4):489-95
pubmed: 22619364
Dis Esophagus. 2013 Nov-Dec;26(8):776-81
pubmed: 22925366
Neurogastroenterol Motil. 2013 Jan;25(1):47-52.e5
pubmed: 22963642
Aliment Pharmacol Ther. 2012 Nov;36(10):950-8
pubmed: 22994460
Gastroenterology. 2013 Dec;145(6):1230-6.e1-2
pubmed: 23954315
Gastrointest Endosc. 2014 Apr;79(4):577-85.e4
pubmed: 24275329
Gastroenterol Clin North Am. 2014 Jun;43(2):243-56
pubmed: 24813513
Aliment Pharmacol Ther. 2015 Apr;41(7):662-70
pubmed: 25684441
Aliment Pharmacol Ther. 2015 May;41(10):1016-22
pubmed: 25809664
Allergy. 2015 Dec;70(12):1633-9
pubmed: 26304142
Scand J Gastroenterol. 2016 Mar;51(3):257-62
pubmed: 26446708
Pediatr Pulmonol. 2016 May;51(5):478-83
pubmed: 26509459
Aliment Pharmacol Ther. 2016 Jan;43(1):3-15
pubmed: 26510832
Best Pract Res Clin Gastroenterol. 2015 Oct;29(5):771-781
pubmed: 26552776
Gut. 2016 Mar;65(3):524-31
pubmed: 26685124
World J Gastrointest Pharmacol Ther. 2016 Feb 6;7(1):21-32
pubmed: 26855809
Ann Allergy Asthma Immunol. 2017 May;118(5):582-590.e2
pubmed: 28366582
Neurogastroenterol Motil. 2018 Jan;30(1):null
pubmed: 28745828